Virus-like particle vaccines: immunology and formulation for clinical translation.

ABSTRACT:

Introduction

Virus-like particle (VLP) vaccines face significant challenges in their translation from laboratory models, to routine clinical administration. While some VLP vaccines thrive and are readily adopted into the vaccination schedule, others are restrained by regulatory obstacles, proprietary limitations, or finding their niche amongst the crowded vaccine market. Often the necessity to supplant an existing vaccination regimen possesses an immediate obstacle for the development of a VLP vaccine, despite any preclinical advantages identified over the competition. Novelty, adaptability and formulation compatibility may prove invaluable in helping place VLP vaccines at the forefront of vaccination technology.

Areas covered

The purpose of this review is to outline the div

SUBMITTER: Donaldson B 

PROVIDER: S-EPMC7103734 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature